FI3571225T3 - Parannettuja seerumialbumiinin sitojia - Google Patents
Parannettuja seerumialbumiinin sitojia Download PDFInfo
- Publication number
- FI3571225T3 FI3571225T3 FIEP18707848.0T FI18707848T FI3571225T3 FI 3571225 T3 FI3571225 T3 FI 3571225T3 FI 18707848 T FI18707848 T FI 18707848T FI 3571225 T3 FI3571225 T3 FI 3571225T3
- Authority
- FI
- Finland
- Prior art keywords
- amino acid
- acid sequence
- compound
- polypeptide
- variable domain
- Prior art date
Links
- 102000007562 Serum Albumin Human genes 0.000 title 1
- 108010071390 Serum Albumin Proteins 0.000 title 1
- 239000011230 binding agent Substances 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 229920001184 polypeptide Polymers 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- 108060003951 Immunoglobulin Proteins 0.000 claims 9
- 102000018358 immunoglobulin Human genes 0.000 claims 9
- 210000004899 c-terminal region Anatomy 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762446988P | 2017-01-17 | 2017-01-17 | |
| PCT/EP2018/051083 WO2018134235A1 (en) | 2017-01-17 | 2018-01-17 | Improved serum albumin binders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3571225T3 true FI3571225T3 (fi) | 2024-10-31 |
Family
ID=61521465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18707848.0T FI3571225T3 (fi) | 2017-01-17 | 2018-01-17 | Parannettuja seerumialbumiinin sitojia |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11414481B2 (enExample) |
| EP (3) | EP4442709A3 (enExample) |
| JP (3) | JP7219220B2 (enExample) |
| KR (2) | KR102662499B1 (enExample) |
| CN (2) | CN110191896B (enExample) |
| AU (2) | AU2018209151B2 (enExample) |
| BR (1) | BR112019014599A2 (enExample) |
| CA (1) | CA3050575A1 (enExample) |
| DK (1) | DK3571225T3 (enExample) |
| ES (1) | ES2991459T3 (enExample) |
| FI (1) | FI3571225T3 (enExample) |
| HR (1) | HRP20241469T1 (enExample) |
| HU (1) | HUE068790T2 (enExample) |
| IL (2) | IL267894B2 (enExample) |
| LT (1) | LT3571225T (enExample) |
| MX (2) | MX2019008496A (enExample) |
| PT (1) | PT3571225T (enExample) |
| RS (1) | RS66117B1 (enExample) |
| SG (2) | SG11201906264YA (enExample) |
| SI (1) | SI3571225T1 (enExample) |
| WO (1) | WO2018134235A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| NZ780183A (en) * | 2011-06-23 | 2024-12-20 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| CN117164710A (zh) | 2016-12-07 | 2023-12-05 | 埃博灵克斯股份有限公司 | 改进的血清白蛋白结合免疫球蛋白单可变结构域 |
| SG10202108973SA (en) * | 2017-01-17 | 2021-09-29 | Ablynx Nv | Improved serum albumin binders |
| ES2991459T3 (es) * | 2017-01-17 | 2024-12-03 | Ablynx Nv | Ligantes de albúmina sérica mejorados |
| CA3163764A1 (en) | 2019-12-06 | 2021-06-10 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l |
| CN114981300B (zh) | 2019-12-06 | 2025-10-31 | 艾伯霖克斯公司 | 包含靶向TNFα和IL-23的免疫球蛋白单个可变结构域的多肽 |
| AU2020400938A1 (en) | 2019-12-09 | 2022-07-28 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP |
| WO2021140205A1 (en) | 2020-01-10 | 2021-07-15 | Confo Therapeutics N.V. | Methods for generating antibodies and antibody fragments and libraries comprising same |
| EP4126971A1 (en) | 2020-03-30 | 2023-02-08 | Ablynx N.V. | Method for the production and purification of multivalent immunoglobulin single variable domains |
| CA3195687A1 (en) | 2020-09-25 | 2022-03-31 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l |
| WO2022129637A1 (en) | 2020-12-18 | 2022-06-23 | Ablynx Nv | T cell recruiting polypeptides based on tcr alpha/beta reactivity |
| KR20230123497A (ko) | 2020-12-18 | 2023-08-23 | 아블린쓰 엔.브이. | IL-6 및 TNF-α를 표적화하는 면역글로불린 단일 가변도메인을 포함하는 폴리펩티드 |
| IL303783A (en) | 2020-12-18 | 2023-08-01 | Sanofi Sa | Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor |
| EP4448574A1 (en) | 2021-12-17 | 2024-10-23 | Ablynx N.V. | Polypeptides comprising immunoglobulin single variable domains targeting tcralphabeta, cd33 and cd123 |
| US20240109965A1 (en) | 2022-06-14 | 2024-04-04 | Ablynx N.V. | Immunoglobulin single variable domains targeting t cell receptor |
| JP2025526384A (ja) | 2022-07-27 | 2025-08-13 | アブリンクス エン．ヴェー． | 新生児型Ｆｃ受容体の特異的エピトープに結合するポリペプチド |
| WO2024084203A1 (en) | 2022-10-18 | 2024-04-25 | Isogenica Limited | Single domain antibodies binding to albumin |
| TW202440614A (zh) | 2022-12-23 | 2024-10-16 | 比利時商艾伯霖克斯公司 | 基於蛋白質的接合載體 |
| AU2024207151A1 (en) | 2023-01-09 | 2025-06-19 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| TW202448926A (zh) | 2023-02-17 | 2024-12-16 | 比利時商艾伯霖克斯公司 | 結合新生兒fc受體之多肽 |
| TW202444757A (zh) | 2023-03-14 | 2024-11-16 | 美商奧迪希治療公司 | 抗cd25抗原結合蛋白及其用途 |
| TW202448951A (zh) | 2023-05-17 | 2024-12-16 | 美商奧迪希治療公司 | 經修飾之單域抗體 |
| KR102822958B1 (ko) * | 2023-05-23 | 2025-06-20 | 대한민국(해양경찰청 해양경찰연구센터장) | 고래 불법포획 감식용 신속진단키트 |
| WO2024261235A1 (en) | 2023-06-22 | 2024-12-26 | Ablynx Nv | Chimeric proteins for modulating cytokine receptor activity |
| TW202515917A (zh) | 2023-06-29 | 2025-04-16 | 美商奧迪希治療公司 | 抗trailr2抗原結合蛋白及其用途 |
| AR133188A1 (es) | 2023-07-05 | 2025-09-03 | Ablynx Nv | ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG |
| WO2025051767A1 (en) | 2023-09-04 | 2025-03-13 | Sanofi | Polypeptides for use in the treatment of glypican-3-expressing tumours |
| AR133903A1 (es) | 2023-09-22 | 2025-11-12 | Ablynx Nv | Agentes de unión de albúmina bi- y multivalentes |
| TW202530265A (zh) | 2023-10-13 | 2025-08-01 | 美商奧迪希治療公司 | 抗cdh17抗原結合蛋白及其用途 |
| WO2025099632A1 (en) | 2023-11-08 | 2025-05-15 | Sanofi | Cd25 based lysosomal degrader and uses thereof |
| WO2025114529A1 (en) | 2023-12-01 | 2025-06-05 | Ablynx Nv | Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety |
| WO2025133253A2 (en) | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based conjugation carriers for intranuclear delivery |
| US20250236673A1 (en) | 2023-12-22 | 2025-07-24 | Ablynx N.V. | Protein-based carriers for site-specific amine conjugation |
| WO2025217240A1 (en) | 2024-04-10 | 2025-10-16 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| WO2025217488A1 (en) * | 2024-04-12 | 2025-10-16 | Paragon Therapeutics, Inc. | Albumin binding proteins and methods of use |
| US12459994B2 (en) | 2024-04-12 | 2025-11-04 | Paragon Therapeutics, Inc. | Albumin binding proteins and methods of use |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| BR9813276A (pt) | 1997-10-27 | 2000-08-22 | Unilever Nv | Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma |
| US6742038B2 (en) | 2000-04-07 | 2004-05-25 | Danger, Inc. | System and method of linking user identification to a subscriber identification module |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| DK1517921T3 (da) | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| EP3299393A1 (en) | 2002-11-08 | 2018-03-28 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| NZ540771A (en) | 2003-01-10 | 2009-05-31 | Ablynx Nv | Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen |
| KR20070086896A (ko) | 2004-12-02 | 2007-08-27 | 도만티스 리미티드 | 항ｉｌ1ｒ1 단일 도메인 항체 및 치료적 용도 |
| CN103254309B (zh) | 2005-05-18 | 2017-09-26 | 埃博灵克斯股份有限公司 | 针对肿瘤坏死因子α的改进的纳米体TM |
| CN101213214B (zh) | 2005-05-20 | 2014-06-25 | 埃博灵克斯股份有限公司 | 针对冯威勒布兰特因子的单一结构域vhh抗体 |
| EP1957537A2 (en) | 2005-12-01 | 2008-08-20 | Domantis Limited | Competitive domain antibody formats that bind interleukin 1 receptor type 1 |
| KR20080077238A (ko) | 2005-12-01 | 2008-08-21 | 도만티스 리미티드 | 인터루킨 1 수용체 타입 1에 결합하는 비경쟁적 도메인항체 포맷 |
| FR2894741B1 (fr) | 2005-12-08 | 2009-12-04 | Centre Nat Etd Spatiales | Chaine de reception par satellite |
| WO2007085814A1 (en) | 2006-01-24 | 2007-08-02 | Domantis Limited | Fusion proteins that contain natural junctions |
| EP2057191A1 (en) | 2006-08-18 | 2009-05-13 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| AU2007293614A1 (en) | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| CN101796072B (zh) | 2007-05-24 | 2014-09-24 | 埃博灵克斯股份有限公司 | 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽 |
| CN101970490A (zh) | 2007-11-27 | 2011-02-09 | 埃博灵克斯股份有限公司 | 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽 |
| DE102008023620A1 (de) | 2008-05-15 | 2009-11-19 | Mettler-Toledo (Albstadt) Gmbh | Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf |
| US9212226B2 (en) | 2008-05-16 | 2015-12-15 | Ablynx N.V. | Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same |
| WO2010035012A1 (en) * | 2008-09-26 | 2010-04-01 | Ucb Pharma S.A. | Biological products |
| WO2010130832A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions |
| BR112012001681A2 (pt) | 2009-07-16 | 2019-09-24 | Graxo Group Ltd | domínios variáveis de ligação de anti-albumina sérica aperfeiçoados |
| BR112012007374A2 (pt) | 2009-09-30 | 2019-09-24 | Glaxo Group Ltd | composição, formulação oral, injetável, inalável ou nebulizável, e, ácido nucleico isolado ou recombinante |
| US9012609B2 (en) | 2010-08-13 | 2015-04-21 | Glaxosmithkline Intellectual Property Development Limited | Anti-serum albumin binding variants |
| KR20130055663A (ko) | 2010-08-20 | 2013-05-28 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 개선된 항-혈청 알부민 결합 변이체 |
| US11644471B2 (en) * | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| NZ780183A (en) | 2011-06-23 | 2024-12-20 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP3363813A1 (en) * | 2011-06-23 | 2018-08-22 | Ablynx NV | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains |
| EP2723771B1 (en) | 2011-06-23 | 2019-09-11 | Ablynx NV | Serum albumin binding proteins |
| US20150344568A1 (en) * | 2011-06-23 | 2015-12-03 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| WO2012174741A1 (en) | 2011-06-24 | 2012-12-27 | Google Inc. | Determining cross-language query suggestion based on query translations |
| PE20141522A1 (es) | 2011-08-17 | 2014-11-17 | Glaxo Group Ltd | Proteinas y peptidos modificados |
| US20130129727A1 (en) * | 2011-11-17 | 2013-05-23 | Nanjingjinsirui Science & Technology Biology Corporation | Methods and systems for increasing protein stability |
| WO2014037419A1 (en) | 2012-09-04 | 2014-03-13 | Vib Vzw | Immunoglobulin single variable domains directed against cd74 and uses derived thereof |
| US20140186365A1 (en) * | 2013-01-03 | 2014-07-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Antibodies that specifically bind to serum albumin without interfering with albumin's capability to interact with the fcrn |
| WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
| PT3248986T (pt) | 2014-05-16 | 2022-04-05 | Ablynx Nv | Domínios variáveis de imunoglobulina |
| WO2016118733A1 (en) | 2015-01-21 | 2016-07-28 | Inhibrx Biopharma LLC | Non-immunogenic single domain antibodies |
| EP3611192B1 (en) | 2015-05-13 | 2025-03-05 | Ablynx N.V. | T cell recruiting polypeptides based on tcr alpha/beta reactivity |
| EP3974449A1 (en) * | 2015-11-13 | 2022-03-30 | Ablynx NV | Improved serum albumin-binding immunoglobulin variable domains |
| CA3006398A1 (en) | 2015-11-27 | 2017-06-01 | Ablynx Nv | Polypeptides inhibiting cd40l |
| CN117164710A (zh) | 2016-12-07 | 2023-12-05 | 埃博灵克斯股份有限公司 | 改进的血清白蛋白结合免疫球蛋白单可变结构域 |
| SG10202108973SA (en) * | 2017-01-17 | 2021-09-29 | Ablynx Nv | Improved serum albumin binders |
| ES2991459T3 (es) | 2017-01-17 | 2024-12-03 | Ablynx Nv | Ligantes de albúmina sérica mejorados |
| AR133903A1 (es) * | 2023-09-22 | 2025-11-12 | Ablynx Nv | Agentes de unión de albúmina bi- y multivalentes |
-
2018
- 2018-01-17 ES ES18707848T patent/ES2991459T3/es active Active
- 2018-01-17 RS RS20241215A patent/RS66117B1/sr unknown
- 2018-01-17 EP EP24191393.8A patent/EP4442709A3/en active Pending
- 2018-01-17 KR KR1020197024113A patent/KR102662499B1/ko active Active
- 2018-01-17 AU AU2018209151A patent/AU2018209151B2/en active Active
- 2018-01-17 DK DK18707848.0T patent/DK3571225T3/da active
- 2018-01-17 IL IL267894A patent/IL267894B2/en unknown
- 2018-01-17 CN CN201880007313.6A patent/CN110191896B/zh active Active
- 2018-01-17 JP JP2019538382A patent/JP7219220B2/ja active Active
- 2018-01-17 EP EP24191388.8A patent/EP4442707A3/en active Pending
- 2018-01-17 SG SG11201906264YA patent/SG11201906264YA/en unknown
- 2018-01-17 FI FIEP18707848.0T patent/FI3571225T3/fi active
- 2018-01-17 PT PT187078480T patent/PT3571225T/pt unknown
- 2018-01-17 HR HRP20241469TT patent/HRP20241469T1/hr unknown
- 2018-01-17 CA CA3050575A patent/CA3050575A1/en active Pending
- 2018-01-17 CN CN202311123454.3A patent/CN117285623A/zh active Pending
- 2018-01-17 SG SG10202108972RA patent/SG10202108972RA/en unknown
- 2018-01-17 MX MX2019008496A patent/MX2019008496A/es unknown
- 2018-01-17 WO PCT/EP2018/051083 patent/WO2018134235A1/en not_active Ceased
- 2018-01-17 HU HUE18707848A patent/HUE068790T2/hu unknown
- 2018-01-17 SI SI201831169T patent/SI3571225T1/sl unknown
- 2018-01-17 US US16/477,918 patent/US11414481B2/en active Active
- 2018-01-17 BR BR112019014599-0A patent/BR112019014599A2/pt unknown
- 2018-01-17 EP EP18707848.0A patent/EP3571225B1/en active Active
- 2018-01-17 KR KR1020247002265A patent/KR20240013861A/ko not_active Ceased
- 2018-01-17 IL IL312292A patent/IL312292A/en unknown
- 2018-01-17 LT LTEPPCT/EP2018/051083T patent/LT3571225T/lt unknown
-
2019
- 2019-07-16 MX MX2023005374A patent/MX2023005374A/es unknown
-
2022
- 2022-06-29 US US17/852,604 patent/US20230060574A1/en active Pending
- 2022-12-08 JP JP2022196232A patent/JP7628996B2/ja active Active
-
2024
- 2024-11-22 JP JP2024204085A patent/JP2025026992A/ja active Pending
-
2025
- 2025-05-13 AU AU2025203430A patent/AU2025203430A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3571225T3 (fi) | Parannettuja seerumialbumiinin sitojia | |
| FI3571224T3 (fi) | Parannettuja seerumialbumiinin sitojia | |
| US10604579B2 (en) | Antibody against a complex between human GARP and latent TGF-β | |
| RU2022101604A (ru) | Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином | |
| JP2020511113A5 (enExample) | ||
| JP7001474B2 (ja) | 非免疫原性単一ドメイン抗体 | |
| US20210230269A1 (en) | Immune-stimulating monoclonal antibodies against human interleukin-2 | |
| JP2020515518A5 (enExample) | ||
| JP2020506898A5 (enExample) | ||
| HRP20220080T1 (hr) | Poboljšane imunoglobulinske varijabilne domene koje vežu serumski albumin | |
| RU2012129735A (ru) | Антитела к her3 и их применения | |
| JP2016511277A5 (enExample) | ||
| JP2014519318A5 (enExample) | ||
| JP2020505001A (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| JP2019503990A (ja) | 改良された血清アルブミン結合剤 | |
| RU2010111751A (ru) | Гуманизированные антитела к cxcr5, их производные и их применение | |
| JP2017522903A (ja) | Ｃｄ１２７に対する抗体 | |
| JP2017520575A5 (enExample) | ||
| EA201290525A1 (ru) | Новые антитела-антагонисты, их fab-фрагменты против gpvi и способы их применения | |
| CN106573985A (zh) | 抗vasa抗体及其生产方法和用途 | |
| KR20150134319A (ko) | 인간화 항 hmgb1 항체 또는 그의 항원 결합성 단편 | |
| RU2016137486A (ru) | Новое антитело против pai-1 человека | |
| RU2380377C2 (ru) | Nogo-A-СВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ И ИХ ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ | |
| Zhang et al. | Overcoming antigen tolerance to develop GB22–45-2, an anti-DKK1 antibody for gastric cancer | |
| RU2022112308A (ru) | Полипептиды, которые связываются с компонентом комплемента c5 или сывороточным альбумином, и их белки слияния |